SCHEMBL14007013

SCHEMBL14007013

Cc1cccc(NC(=O)C2CN(C(=O)C[C@H](N)Cc3cc(F)c(F)cc3F)C2)n1

nearest known ligand 0.52

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 20/20 0.52
DPP9 Q86TI2 9/20 0.52
CYP3A4 P08684 3/20 0.48
DPP7 Q9UHL4 2/20 0.46
DPP8 Q6V1X1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14007014 0.79 DPP4 (0.51) DPP4DPP9CYP3A4DPP7DPP8
SCHEMBL5772718 0.76 DPP4 (0.52) DPP4DPP9DPP7DPP8
SCHEMBL5772714 0.76 DPP4 (0.52) DPP4DPP9DPP7DPP8
SCHEMBL14007010 0.74 DPP4 (0.58) DPP4DPP9CYP3A4
SCHEMBL14006996 0.70 DPP4 (0.58) DPP4DPP9CYP3A4DPP7DPP8
SCHEMBL25840236 0.70 DPP4 (0.77) DPP4DPP9CYP3A4DPP7DPP8
SCHEMBL4399771 0.69 DPP4 (0.67) DPP4DPP9CYP3A4DPP7DPP8
SCHEMBL3387787 0.69 RAB9A (0.64)
SCHEMBL3387780 0.69 RAB9A (0.64)
SCHEMBL3387781 0.69 RAB9A (0.64)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275086-A1 Dpp-Iv Inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2008-11-06 US disclosed
US-20080275086-A1 Dpp-Iv Inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275086-A1 Dpp-Iv Inhibitors DPP4, DPP7, DPP3 DPP4 1/4885DPP9 4/4885CYP3A4 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.